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Abstract 
Background: Statins have been associated with later life long-term care admission in 
observational studies.  However, by preventing vascular events, statins may also prevent or 
delay admission.  We wished to determine statin and long-term care admission associations in 
a randomised controlled trial context and describe associations between long-term care 
admission and other clinical and demographic factors  
Methods: We used extended follow-up of two randomised trial populations, using national 
data to assign the long-term care admission outcome.  We included individuals screened or 
recruited to two large randomised trials of pravastatin 40mg daily: the West of Scotland 
Coronary Prevention Study (WOSCOPS) and Pravastatin in elderly individuals at risk of 
vascular disease (PROSPER). We described univariable and multivariable analyses of 
potential predictors of long-term care admission with corresponding survival curves of 
incident long-term care admission and analyses adjusted for competing risk  
Results: In total 11,015 (10%) of the trial participants were admitted to long-term care. There 
was no difference between the participants in the statin or placebo arm of either trial 
regarding admissions to long-term care. On multivariable analyses, independent associations 
with incident long-term care admission in PROSPER trial were, age (HR:1.06 per year 
[95%CI:1.03-1.09]) and male sex (HR:0.72 [95%CI:0.53-0.99]).  In the WOSCOPS age 
(HR:1.12 per year [95%CI:1.10-1.13]) and increasing social deprivation (HR:1.05 
[95%CI:1.03-1.08]) were associated with incident long-term care admission.  
Conclusion: We did not demonstrate association between historical statin use and future long-
term care admission.  The strongest associations with incident long-term care admission were 
non-modifiable factors of age, sex and socioeconomic deprivation.    
 
Keywords: long-term care; statin; data linkage; outcome; predictor  
Key points: 
Long-term care admission is an important event for older adults and a potentially useful 
outcome measure for trials.  
Routinely collected health and social care can be used to assign long term care admission 
status.  
Statin use in mid or late adult life is not associated with subsequent long-term care admission. 
 
  
1 Introduction 
The benefits of statins (HMG-CoA reductase inhibitors) for reducing cardiovascular events 
and mortality are well described for older adults.(1)  Statins have pleiotropic effects and 
various non-cardiovascular benefits of statins have been demonstrated.(2)  The potential for 
statins to influence common syndromes of older age, such as functional or cognitive decline, 
has also been postulated.(3)  These statin effects in older age may not necessarily be 
beneficial and observational data have suggested possible adverse events in relation to 
physical and cognitive function.(4)   
 
Arguably the outcomes of greatest relevance to older adults are not mortality or incident 
vascular events but maintaining functional independence.  In other research areas, older 
adults have expressed that the most desired effect of an intervention is not to prolong life per 
se but to maintain cognitive and functional ability.(5)  The complex construct of 
independence can be difficult to measure robustly at a population level.(6)  However, 
admission to institutional long-term care could be viewed as an inversely related measure of 
independence, where care needs exceed those which can be met in the community.  Acre-
home admission would be especially relevant to older adults, many of whom have stated that 
institutionalisation would be a ‘fate worse than death’.(7)  Admission to long-term care is 
relatively common, affecting 2-5% of the adult population worldwide,(8) and so has potential 
as a clinical trial outcome of relevance to older adults, physicians and policy makers.   
 
Utilising extended follow-up data from existing statin trial cohorts, allows evaluation of the 
effects of risk modification on later life and allows capture of novel outcomes not collected 
during the initial study period.   
 
 1.1 Aims  
Our aim was to describe associations with long-term care admission using populations from 
randomised controlled trials (RCTs) of statins.  Our primary hypothesis was that statin 
exposure in mid to older age would be associated with later long-term care admission.  A 
secondary aim was to assess the feasibility of using admission to long-term care as a trial 
outcome surrogate for functional decline.  
 
2 Methods 
We conducted extended follow-up of the participants and screenees from two large RCTs of 
the statin Pravastatin: the West of Scotland Coronary Prevention Study (WOSCOPS)(8) and 
Pravastatin in elderly individuals at risk of vascular disease (PROSPER).(9)  
 
2.1 Trial data sources 
WOSCOPS was a primary prevention trial conducted in Scotland, UK between the years of 
1989 and 1991 and included male participants aged 45-64 with raised plasma cholesterol 
levels.(9)  PROSPER was an international trial conducted between 1997 and 1999 for men 
and women aged 70-82 who had elevated vascular risk or existing vascular disease.(10)  Both 
evaluated the use of Pravastatin, at a dose of 40mg nocte, in a randomised placebo-controlled 
design.  Comprehensive description of baseline characteristics have been published.(11,12) 
Mean duration of in-trial statin exposure was 4.9 years for WOSCOPS(13) and 3.2 years for 
PROSER.(10) Only participants recruited at the Scottish site of PROSPER were included, as 
outcome ascertainment relied on residency in Scotland.  All participants and screenees were 
eligible for inclusion, using baseline data collected at the time of study evaluation and 
recruitment and linked to data collected through national health and social care services. 
 2.2 Definition of covariates 
Basic demographic information was available for the entire cohort including age, sex and 
socioeconomic status and there were also some common cardiovascular risk factors.  Other 
clinical and demographic data collected at baseline differed between the studies and so the 
two datasets were not combined. Full details on how the covariates were operationalised are 
available from the published protocols for the two studies.(14, 15) Socioeconomic status was 
evaluated using the Carstairs index,(14) an area-based measure of deprivation, based on 
postcode of residence. The measure has seven categories, with an increase in category 
indicative of greater material deprivation.(17) Both sets of trial participants were categorised 
based on whether they were randomised to the statin arm of the trial in which they 
participated.   
 
2.3 Outcomes 
The outcomes of interest were admission to long-term care and death. Long-term care 
admission was defined as being recorded as residing in long-term care at any point during the 
period 2012-2015.  To assign the outcomes we used a variety of nationally (Scottish) 
collected data sources.(18)  To ensure that the long-term care data were robust we 
triangulated three datasets: The Prescribing Information System (which indicates if a drug 
prescription was issued to a patient registered in a long-term care facility); the Scottish 
mortality registers (which indicate if a patient attending secondary care was discharged to a 
long-term care facility); the care-home census (a national annual census of long-term care 
residents).  We described mortality following study completion using National Records 
Scotland Death Registrations data.   
 
 2.4 Data linkage 
Identifiers for screenees and participants in the clinical trials were securely supplied for 
linkage with national centrally-held routine data sources including names, date of birth, full 
address and postcode.  Each individual was then assigned to a national unique identifier that 
is used in Scotland, the community health index (CHI), where available.  The CHI is also 
used within all the routine data sources of interest and this allows individual patient level  
linkage of datasets.   
For our initial study we were interested in the care home status at specific time points. To this 
end, given the differences in coverage, it was necessary to harmonise the four possible data 
sources to analysis.  To allow harmonisation across data sources with differing temporal 
coverage, we focussed on care home resident status for the period 2012 onwards.  Event 
based reports (eg from  PIS, SMR, NRS) were not considered if out with the time window of 
interest.   
Following linkage, all identifiable information was removed before the data were made 
available to the research team through a secured network (safe haven).  Data management 
and analysis was performed at the Robertson Centre for Biostatistics, University of Glasgow.  
 
2.5 Statistical methods 
We described univariable and multivariable adjusted associations with care-home residence 
for PROSPER and WOSCOPS separately.  For our primary analysis of statin exposure, we 
ran ‘survival’ curves using the Kaplan-Meier method and Time to Event Analysis using Cox 
proportional hazards models to analyse for association of predictors individually and in 
multiple regression analyses, censoring on death.  Subsequently competing risk models for 
residence in a long-term care facility or death were created for participants in the two trials. 
 2.6 Approvals 
All participants from WOSCOPS and PROSPER consented to the use of their medical 
records for follow-up.  An ethics application was made using the Integrated Research 
Application System and approved by NHS Greater Glasgow & Clyde Health Board (NHS 
GG&C Board Approval) and the Public Benefit and Privacy Panel provided permission to 
link these data to national health and social care data (eDRIS: 1516-0130).  The funding 
source (Chief Scientist Office, Scotland) played no part in the analyses or interpretation of 
the data. 
 
3 Results 
A total of 106,242 participants from the original screened population of 117,166 (91%) were 
indexed and linked to national health and care records.  At March 2015, 56,090 (53%) of 
participants had died. Between 2012-2015, 11,015 (10%) were identified in routine data 
sources as having been admitted to long-term care.  There were 608/6574 (9%) WOSCOPS 
participants admitted to long-term care and from PROPSER 482/2033 (24%). 
 
There was no association between in-trial statin exposure and incident long-term care 
admission. Long-term care residents from the PROSPER participants had higher baseline 
age, were more likely to be female, had higher diastolic blood pressure, higher total 
cholesterol, were more likely to be smokers, and were more likely to have a history of 
hypertension, myocardial infarction, peripheral arterial disease and claudication.(Table 1)  
Long-term care residents from WOSCOPS had higher baseline age, systolic blood pressure, 
had lower socioeconomic status based on Carstairs category and were more likely to be 
current smokers.(Table 2) 
 On multivariable analyses, independent associations with incident long-term care admission 
in the PROSPER cohort were, age (HR:1.06 per year [95%CI:1.03-1.09]) and a lower risk for 
those of male sex (HR:0.72 [95%CI:0.53-0.99]).  In the WOSCOPS cohort independent 
associations were age (HR:1.12 per year [95%CI:1.10-1.13]); increasing social deprivation 
(HR:1.05 [95%CI:1.03-1.08]) and smoking, with current smokers having fewer long-term 
care admissions (HR:0.76 [95%CI:0.62-0.95]). There was no difference between statin and 
placebo groups in terms of time to long-term care.(Figure 1)  Using competing risk models 
for death and admission to long-term care there were no between group differences.( Figures 
2 & 3) 
 
4 Discussion 
We did not show a difference in long-term care admission between those prescribed statin or 
placebo during the two large RCTS.  Admission to long-term care can be considered a proxy 
for frailty and functional decline, our data would suggest no legacy effect of mid to later life 
statin prescribing on these important outcomes.  This is aligned with other data describing 
statins and functional decline.(3, 4)  An alternative interpretation of our results is that we did 
not demonstrate any statin related harm.  Previous studies have suggested the possibility of 
statins increasing rates of institutionalisation for certain patient groups.(19)  The potency and 
dose of statin used in the two RCTs is modest by contemporary standards and it remains 
possible that high dose potent statins may have effects on patterns of admission to long-term 
care.       
 
The strongest, independent associations for incident care-home admission were age, sex, 
socio-economic status and smoking.  The association of smoking with reduced care-home 
status seems counter intuitive and not in keeping with our understanding of the effect on 
smoking in older age.(20) This finding is likely a result of survival bias and emphasises the 
importance of competing risks analyses in this field of research.  A recent systematic review 
of associations with care-home admission from hospital also reported the importance of age 
and sex.(21)  Other factors in this review with strong association including dementia and 
disability could not be assessed in our study as these were exclusion criteria for the included 
studies.  In reviews looking at long-term care admission from community settings, dementia 
and factors relating to support networks and carer burden seem to be associated with this 
decision.(22)  These findings highlight that admission to long-term care is a multi-faceted 
decision and only certain aspects of this process could plausibly be influenced by statin 
prescribing. 
 
There are several strengths to our approach.  We used multi-modal data to assign care-home 
status following best practice in ‘big data’ research.(23) The ability to link data from clinical 
trial cohorts to routinely collected health and social care data offers the potential to 
economically ascertain longer-term outcomes than would be possible within the primary 
study.  Our results suggest that is feasible to use routinely collected health and social care 
data to assign outcomes that may be of greatest relevance to older adults – in this case, using 
admission to long—term care as a surrogate for cognitive and functional decline.  By using 
data from RCTS we have large numbers of study quality data.  Baseline randomisation 
should avoid those biases associated with observational data on statins (for example, 
confounding by indication; healthy user bias; healthy tolerater bias).  Our previous work on 
the long-term follow-up of the WOSCOPS and PROSPER trials has demonstrated the 
additional scientific value of extended follow-up of these clinical trial populations and of 
record linkage to national datasets.(1)   
 However, there are limitations to our methodology.  For our analysis of statins we have not 
corrected for life course statin exposure.  Ideally we would have corrected our analyses with 
individual patient level data regarding treatment modification, adherence and achieved levels 
of LDL cholesterol.  In population based analyses this level of granularity is not possible.  
However, we know from other studies that adherence and persistence are important issues 
particularly in the older adult population.(24)  We also recognise that we may have missed 
incident care-home admission if it occurred early after trial and the patient was no longer 
resident during the time periods we selected for analyses.   
 
The majority of older adults are now prescribed statins at some point (25) and it seems likely 
that many in the placebo arm of the original trials will have eventually been prescribed statin.  
This cross-over may weaken the power of our analysis to demonstrate a modest statin effect.  
Thus, our analysis can only tell us about a potential legacy effect of previous statin 
administration.   Describing the future effects of earlier life statin exposure remains a valid 
question.  In other longer term follow-up studies of statin trials a persisting benefit from 
earlier treatment is consistently observed.(26,27).  For example, after the end of the 
WoSCOPS trial, use of lipid-lowering therapy during the first 5 years of extended follow-up 
was monitored by review of case records (in the original pravastatin and placebo groups 
respectively proportions on statin therapy were 28.6% and 24.3% at 1 year post-trial, 33.6% 
and 29.4% at 3 years and 38.7% and 35.2% at 5 years).(1)  That the initial treatment arm 
continues to show differential cardiovascular and other outcomes speaks to the legacy effect 
of statin exposure earlier in life.  Our analysis had a specific focus around functional decline 
and we recognise that, despite the increasing numbers of large trials of statin in older adults, 
many questions remain around  statins in older age.(28) 
 We did not demonstrate association between several years of statin use in mid or later life and 
future long-term care admission and a direct link between statins and admission to long-term 
care seems unlikely.  The strongest associations with incident long-term care admission were 
non-modifiable factors of age and sex and socioeconomic deprivation.    
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Tables 
Table 1: Characteristics of PROSPER subjects 
Variable 
 
All subjects 
N=2033 
No care-
home 
N=1551 
Care-home 
N=482 
P-
value 
Age (years) 
Mean 
(SD) 
75.8 (3.3) 75.6 (3.3) 76.4 (3.4) 
< 
0.001  
Female N (%) 1155 (56.8%) 843 (54.4%) 312 (64.7%) 
< 
0.001 
Randomised to statin N (%) 1027 (50.5%) 786 (50.7%) 241 (50.0%) 0.835 
SBP (mmHg) 
Mean 
(SD) 
153.6 (21.2) 153.4 (21.0) 154.3 (21.9) 0.455 
DBP (mmHg) 
Mean 
(SD) 
82.6 (10.6) 82.3 (10.6) 83.4 (10.4) 0.038 
Total cholesterol (mmol/L) 
Mean 
(SD) 
5.7 (1.0) 5.7 (1.0) 5.8 (1.0) 0.025 
LDL cholesterol (mmol/L) 
Mean 
(SD) 
3.9 (0.8) 3.8 (0.8) 3.9 (0.8) 0.063 
HDL cholesterol (mmol/L) 
Mean 
(SD) 
1.3 (0.4) 1.3 (0.4) 1.3 (0.3) 0.063 
Triglycerides (mmol/L) 
Mean 
(SD) 
1.6 (0.7) 1.6 (0.7) 1.6 (0.7) 0.907 
Variable 
 
All subjects 
N=2033 
No care-
home 
N=1551 
Care-home 
N=482 
P-
value 
Height (cm) 
Mean 
(SD) 
162.9 (9.3) 163.3 (9.4)] 161.9 (9.1) 0.004 
Weight (kg) 
Mean 
(SD) 
71.1 (13.1) 71.3 (13.1) 70.2 (12.9) 0.095 
BMI (kgm2) 
Mean 
(SD) 
26.7 (4.3) 26.7 (4.3) 26.8 (4.4) 0.890 
Barthel index score 
Median 
(IQR) 
20.0 (20.0, 
20.0) 
20.0 (20.0, 
20.0) 
20.0 (20.0, 
20.0) 
0.883 
Instrumental activities of 
daily living  
Median 
(IQR) 
14.0 (14.0, 
14.0) 
14.0 (14.0, 
14.0) 
14.0 (14.0, 
14.0) 
0.843 
MMSE 
Mean 
(SD) 
28.1 (1.5) 28.2 (1.5) 28.1 (1.6) 0.152 
Number of concomitant 
drugs 
Median 
(IQR) 
4.0 (2.0, 5.0) 4.0 (2.0, 5.0) 4.0 (2.0, 5.0) 0.468 
History of vascular disease N (%) 1010 (49.7%) 789 (50.9%) 221 (45.9%) 0.060 
Current Smoker 
Ex Smoker  
N (%) 
N (%) 
545 (26.8%) 
824 (40.5%) 
436 (28.1%) 
641 (41.3%) 
109 (22.6%) 
183 (38.0%) 
0.001 
History of hypertension N (%) 1187 (58.4%) 886 (57.1%) 301 (62.4%) 0.039 
History of diabetes N (%) 178 (8.8%) 132 (8.5%) 46 (9.5%) 0.518 
Variable 
 
All subjects 
N=2033 
No care-
home 
N=1551 
Care-home 
N=482 
P-
value 
History of myocardial 
infarction 
N (%) 297 (14.6%) 242 (15.6%) 55 (11.4%) 0.022 
History of angina N (%) 657 (32.3%) 513 (33.1%) 144 (29.9%) 0.200 
History of claudication N (%) 192 (9.4%) 163 (10.5%) 29 (6.0%) 0.003 
History of PAD surgery N (%) 45 (2.2%) 41 (2.6%) 4 (0.8%) 0.020 
History of stroke or TIA N (%) 222 (10.9%) 163 (10.5%) 59 (12.2%) 0.316 
History of CABG N (%) 45 (2.2%) 35 (2.3%) 10 (2.1%) 1.000 
History of PCI N (%) 73 (3.6%) 57 (3.7%) 16 (3.3%) 0.781 
 
SBP=Systolic blood pressure; DBP=diastolic blood pressure; LDL=Low density lipoprotein; 
HDL=high density lipoprotein; BMI=body mass index; MMSE=mini mental state 
examination; PAD=Peripheral Arterial Disease; TIA=transient ischaemic attack; 
CABG=coronary arterial bypass grafting; PCI=Percutaneous Coronary Intervention 
  
Table 2: Characteristics of WOSCOPS subjects 
Variable 
 
All subjects 
N=6574 
No care-home 
N=5966 
Care-home 
N=608 
P-value 
Age (years) 
Mean 
(SD) 
55.2 (5.5) 54.9 (5.5) 58.3 (4.6) < 0.001  
Randomised to statin N (%) 3294 (50.1%) 2984 (50.0%) 310 (51.0%) 0.670 
SBP (mmHg) 
Mean 
(SD) 
135.5 (17.3) 135.2 (17.2) 138.1 (18.1) < 0.001  
DBP (mmHg) Mean (SD 83.9 (10.3) 83.9 (10.3) 84.1 (10.4) 0.588 
Total chol (mmol/L) 
Mean 
(SD) 
7.0 (0.6) 7.0 (0.6) 7.0 (0.6) 0.743  
HDL cholesterol 
(mmol/L) 
Mean 
(SD) 
1.1 (0.2) 1.1 (0.2) 1.2 (0.2) 0.223 
BMI (kgm2) 
Mean 
(SD) 
26.0 (3.2) 26.0 (3.2) 25.8 (3.1) 0.194 
Mean Carstairs score 
Mean 
(SD) 
0.7 (3.5) 0.6 (3.5) 1.3 (3.8) < 0.001 
Former smoker  
Current smoker  
N (%) 
N (%) 
2254 (34.3%) 
2902 (44.1%) 
2029 (34.0%) 
2663 (44.6%) 
225 (37.0%) 
239 (39.3%) 
0.039 
History of hypertension N (%) 1034 (15.7%) 934 (15.7%) 100 (16.4%) 0.599 
History of diabetes N (%) 75 (1.1%) 66 (1.1%) 9 (1.5%) 0.419 
History of angina N (%) 337 (5.1%) 299 (5.0%) 38 (6.2%) 0.209 
Nobs=Number of observations; Nmiss=Number with missing data 
SBP=Systolic blood pressure; DBP=diastolic blood pressure; LDL=Low density 
lipoprotein; HDL=high density lipoprotein; BMI=body mass index; 
Carstairs=socioeconomic deprivation score 
 
 
 
  
Legends 
Figure 1: Kaplan Meier curve for admission to a care-home for trial participants 
 
Figure 2: Competing risks model for death or admission to a care-home for PROSPER trial 
participants 
 
Figure 3: Competing risks model for death or admission to a care-home for WOSCOPS trial 
participants 
 
 
 
